29 related articles for article (PubMed ID: 15023532)
1. Anti-Algics in the Therapeutic Response of Breast and Urological Cancers.
Matos AC; Lorigo J; Marques IA; Abrantes AM; Jóia-Gomes M; Sa-Couto P; Gonçalves AC; Valentim A; Tavares-Silva E; Figueiredo A; Pires AS; Botelho MF
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203640
[TBL] [Abstract][Full Text] [Related]
2. From Traditional Ethnopharmacology to Modern Natural Drug Discovery: A Methodology Discussion and Specific Examples.
Pirintsos S; Panagiotopoulos A; Bariotakis M; Daskalakis V; Lionis C; Sourvinos G; Karakasiliotis I; Kampa M; Castanas E
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807306
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in opioid receptor mediated effects: Role of androgens.
Sharp JL; Pearson T; Smith MA
Neurosci Biobehav Rev; 2022 Mar; 134():104522. PubMed ID: 34995646
[TBL] [Abstract][Full Text] [Related]
4. CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells.
Frigo DE; Howe MK; Wittmann BM; Brunner AM; Cushman I; Wang Q; Brown M; Means AR; McDonnell DP
Cancer Res; 2011 Jan; 71(2):528-37. PubMed ID: 21098087
[TBL] [Abstract][Full Text] [Related]
5. Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.
Pelekanou V; Notas G; Sanidas E; Tsapis A; Castanas E; Kampa M
Mol Oncol; 2010 Apr; 4(2):135-49. PubMed ID: 20189893
[TBL] [Abstract][Full Text] [Related]
6. Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: study in paraffin tissue sections.
Dambaki C; Kogia C; Kampa M; Darivianaki K; Nomikos M; Anezinis P; Theodoropoulos PA; Castanas E; Stathopoulos EN
BMC Cancer; 2005 Nov; 5():148. PubMed ID: 16293185
[TBL] [Abstract][Full Text] [Related]
7. Could testosterone have a therapeutic role in prostate cancer?
Stamatiou K; Pierris N
Urol J; 2013; 10(1):747-54. PubMed ID: 23504676
[TBL] [Abstract][Full Text] [Related]
8. Opioid peptides in cancer.
Fichna J; Janecka A
Cancer Metastasis Rev; 2004; 23(3-4):351-66. PubMed ID: 15197335
[TBL] [Abstract][Full Text] [Related]
9. The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line.
Kampa M; Papakonstanti EA; Alexaki VI; Hatzoglou A; Stournaras C; Castanas E
Exp Cell Res; 2004 Apr; 294(2):434-45. PubMed ID: 15023532
[TBL] [Abstract][Full Text] [Related]
10. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors.
Papakonstanti EA; Kampa M; Castanas E; Stournaras C
Mol Endocrinol; 2003 May; 17(5):870-81. PubMed ID: 12554777
[TBL] [Abstract][Full Text] [Related]
11. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton.
Kampa M; Papakonstanti EA; Hatzoglou A; Stathopoulos EN; Stournaras C; Castanas E
FASEB J; 2002 Sep; 16(11):1429-31. PubMed ID: 12205037
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.
Lee LF; Louie MC; Desai SJ; Yang J; Chen HW; Evans CP; Kung HJ
Oncogene; 2004 Mar; 23(12):2197-205. PubMed ID: 14767470
[TBL] [Abstract][Full Text] [Related]
13. Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells.
Papadopoulou N; Charalampopoulos I; Alevizopoulos K; Gravanis A; Stournaras C
Exp Cell Res; 2008 Oct; 314(17):3162-74. PubMed ID: 18694745
[TBL] [Abstract][Full Text] [Related]
14. Rapid membrane effect of testosterone in LNCaP cells.
Wang Z; Liu L; Hou J; Wen D; Yan C; Pu J; Ouyang J; Pan H
Urol Int; 2008; 81(3):353-9. PubMed ID: 18931557
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
